Mobile

A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depr...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004006-81

A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depressive symptoms in patients with major depressive disorder improved after 8 months of open treatment with SR58611A (350 mg q12)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy of SR58611A 350 mg q12 compared to placebo in the prevention of relapse / recurrence of depressive symptoms, in sustained responder patients with major depressive disorder, over 6 to 12-month treatment period.

Critère d'inclusion

  • patients with major depressive disorder

Liens